Related Experiment Videos
Cyclophosphamide therapy of severe systemic necrotizing vasculitis
The New England Journal of Medicine
|August 2, 1979
Summary
Cyclophosphamide treatment led to significant remissions in severe systemic necrotizing vasculitis patients, even those with prior corticosteroid toxicity. This immunosuppressive therapy offers a promising alternative for managing this rare autoimmune disease.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Severe systemic necrotizing vasculitis is a serious autoimmune condition.
- Corticosteroids are often used but cause severe toxic side effects.
- Patients in this study had active disease despite corticosteroid treatment.
Purpose of the Study:
- To evaluate the efficacy of cytotoxic agents in treating severe systemic necrotizing vasculitis.
- To assess the long-term remission rates and safety of cyclophosphamide and azathioprine.
Main Methods:
- An 11-year observational study of 17 patients with severe systemic necrotizing vasculitis.
- Daily administration of cyclophosphamide (16 patients) or azathioprine (1 patient).
- Patients were transitioned to alternate-day corticosteroids with continued cytotoxic therapy upon remission.
Main Results:
- Complete and dramatic remissions were observed in 14 out of 17 patients.
- The mean duration of remission was 22 months (range: 2-61 months).
- No recurrence of vasculitis was noted during treatment with cytotoxic agents.
Conclusions:
- Cyclophosphamide and azathioprine are effective in inducing and maintaining remission in severe systemic necrotizing vasculitis.
- Cytotoxic therapy can allow for reduction or discontinuation of corticosteroids, mitigating their side effects.
- Immunosuppressive agents represent a viable treatment option for refractory vasculitis.